Avenda Health, an AI healthcare company specializing in personalized prostate cancer care, has introduced its FDA cleared prostate cancer management platform, Unfold AI™. Now being utilized at a renowned U.S. research hospital, the platform combines patient-specific data from prostate imaging, biopsies, and pathology with deep-learning algorithms to create a tailored cancer estimation map. This innovative 3D map enables physicians to make more informed treatment decisions and plan interventions accordingly.
Dr. Leonard Marks, co-founder and Chief Medical Officer of Avenda Health, shared his enthusiasm for the platform’s potential: “This is a major step forward for the prostate cancer community, and we are beyond thrilled to see a decade of hard work and research pay off. Our mission at Avenda Health is to create a better quality of life for prostate cancer patients and to give urologists a clearer view of the cancer so we can better treat our patients. Unfold AI will improve clinical care and decision making.”
Physicians at the research hospital, including Wayne Brisbane, MD, have adopted the technology in their practice. In clinical trials, guidance from Unfold AI led to changes in treatment recommendations in 28% of cases, often opting for more localized treatment. Based on the results provided by Unfold AI, multiple treatment options can be chosen, such as active surveillance, whole gland treatments like radical prostatectomy and radiation therapy, or soft tissue laser ablation using Avenda Health’s FocalPoint device.
Avenda Health aims to make this groundbreaking technology available to all practices and physicians treating prostate cancer patients, with the goal of improving patient outcomes, preserving quality of life, and establishing a new standard of care. Unfold AI received 510(k) clearance from the U.S. FDA in December 2022. For more information about Avenda Health and its pioneering technology, visit avendahealth.com.
